Clinuvel Starts Preclinical Dosing of New Controlled-Release Peptide Platform VLRX-L

Clinuvel Pharmaceuticals ( (AU:CUV) ) just unveiled an announcement.

Clinuvel Pharmaceuticals has begun dosing in a new preclinical study of VLRX-L, its in-house developed controlled-release liquid injectable peptide platform designed to deliver melanocortin-based and other peptide drugs with reproducible release profiles. The VLRX-L platform is the first novel pharmaceutical technology to emerge from the company’s expanded VALLAURIX Research, Development & Innovation Centre in Singapore, where a multi-year, Singapore Economic Development Board-backed investment is building capabilities in injectable controlled-release formulations, signalling Clinuvel’s ambition to broaden its product pipeline and strengthen its position in peptide-based drug delivery over the coming years, with initial preclinical readouts expected in the second half of 2026.

The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

More about Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic and acute life-threatening disorders, alongside healthcare solutions for specialised populations. A pioneer in photomedicine and melanocortin peptide therapies, its lead product SCENESSE is approved in major markets as the first systemic photoprotective drug for adults with erythropoietic protoporphyria, and the company operates from headquarters in Melbourne with additional bases in Europe, Singapore and the United States.

YTD Price Performance: 1.44%

Average Trading Volume: 89,777

Technical Sentiment Signal: Hold

Current Market Cap: A$634.5M

For a thorough assessment of CUV stock, go to TipRanks’ Stock Analysis page.